Rheumatoid arthritis and herpes zoster: Risk and prevention in those treated with anti-tumour necrosis factor therapy

Annals of the Rheumatic Diseases

Volumn 69, Issue 10, 2010, Pages 1735-1737

  Winthrop, K L ^a   Furst, D E ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; VARICELLA ZOSTER VACCINE; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

EDITORIAL; GROUPS BY AGE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VACCINATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPLICATION; OPPORTUNISTIC INFECTIONS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; OPPORTUNISTIC INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957257774     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.133843     Document Type: Editorial

References (17)

1. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-10.
2. Tubach F, Ravaud P, Salmon-Céron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006;43:e95-100.
3. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76. (Pubitemid 44204996)
4. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010;6:165-74.
5. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4.
6. Yawn BP, Saddi er P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-9.
7. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2008;57(RR-5):1-30; quiz CE2-4.
8. García-Doval I, Pérez-Zafrilla B, Descalzo MA, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010;69:1751-55.
9. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431-8.
10. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
11. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009;48:1364-71.
12. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006;45:1370-5.
13. Descalzo MA, Biobadaser CC, Biobadaser SG. Spanish Registry for adverse events of biologic therapies in rheumatic diseases (BIOBADASER): state report on January 26th 2006. Reumatol Clin 2007;3:4-20.
14. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005;41(Suppl 3):S189-93.
15. Plessner HL, Lin PL, Kohno T, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007;195:1643-50.
16. Marino S, Sud D, Plessner H, et al. Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol 2007;3:1909-24. (Pubitemid 350043407)
17. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.